Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 5/20 | 0.49 |
| ▸ | ITGAV | P06756 | 15/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.48 |
| ▸ | ITGB6 | P18564 | 11/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20488508 | 1.00 | CXCR4 (0.49) | CXCR4ITGAVITGB3ITGB6 | |
| SCHEMBL20486737 | 0.95 | ITGAV (0.51) | ITGAVITGB3ITGB6 | |
| SCHEMBL22893596 | 0.95 | ITGAV (0.51) | ITGAVITGB3ITGB6 | |
| SCHEMBL31241598 | 0.95 | ITGAV (0.51) | ITGAVITGB3ITGB6 | |
| SCHEMBL22893655 | 0.95 | ITGAV (0.51) | ITGAVITGB3ITGB6 | |
| SCHEMBL31241585 | 0.94 | ITGAV (0.52) | ITGAVITGB3ITGB6 | |
| SCHEMBL20487690 | 0.94 | ITGAV (0.52) | ITGAVITGB3ITGB6 | |
| SCHEMBL22893657 | 0.92 | ITGAV (0.51) | CXCR4ITGAVITGB3ITGB6 | |
| SCHEMBL23584032 | 0.91 | CXCR4 (0.51) | CXCR4ITGAVITGB3ITGB6 | |
| SCHEMBL20487371 | 0.88 | ITGAV (0.52) | ITGAVITGB3ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145935-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2024-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145935-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CXCR4 470/4885ITGAV 3/4885ITGB3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.